3PC-013 In this abstract we explain the compounding of bevacizumab eye drops for neovascularisation, some studies have demonstrated their efficacy, it has 1 month stability

<h3>Background and Importance</h3> Vascular endothelial growth factor (VEGF) is a mediator in the process of neovascularisation in the cornea. VEGF inhibitors, such as, bevacizumab are currently one of the treatments of neovascular age-related macular degeneration (AMD). Bevacizumab is a full-length humanised antibody against VEGF and has been approved for use in oncology but is also widely used as an off-label treatment for choroidal neovascularisation, central retina occlusion, proliferative diabetic retinopathy and iris neovascularisation, with good results. Recently, the off-label use of topical as well as subconjunctival bevacizumab has been considered as a new treatment modality for corneal neovascularisation. <h3>Aim and Objectives</h3> The compounding of bevacizumab eye drops in two different concentrations. <h3>Material and Methods</h3> Bevacizumab eye drops in a sterile compounding can be prepared in two different concentrations in vertical laminar flow hood in a sterile environment and applying the Good Manufacturing Practices: Bevacizumab 1% eye drops: in a sterile dropper 10 mL container add 4 mL of bevacizumab (avastin 400 mg/16 mL) and 6 mL of physiological saline solution. Bevacizumab 0.5% eye drops: in a sterile dropper 10 mL container add 2 mL of bevacizumab (avastin 400 mg/16 mL) and 8 mL of physiological saline solution. The recommended stability is 1 month at 2–8°C not open and 7 days at 2–8°C once open. <h3>Results</h3> Bevacizumab eye drops can easily prepared as a sterile compounding and used when the intravitreal syringes of bevacizumab are not appropriate for use. <h3>Conclusion and Relevance</h3> The off-label use of topical bevacizumab for corneal neovascularisation is an option for patients with choroidal neovascularisation, central retina occlusion, proliferative diabetic retinopathy, iris neovascularisation and age-related macular degeneration. <h3>References and/or Acknowledgements</h3> Dastjerdi MH, Al-Arfaj KM, Nallasasmy N, <i>et al</i>. Khalid. Topical bevacizumab in the treatment of corneal neovascularisation: results of a prospective, open-label, non-comparative study. <i>Arch Ophthalmol</i>, 2009, April;<b>127</b>(4):381–389. Monzon Moreno A, Bevacizumab en el tratamiento de la degeneración macular neovascular asociada a la edad. <i>Farm Hosp</i>, 2006;<b>30</b>:387–388. Monzon Moreno A, Camean Fernandez M, Merino Bohorquez V, <i>et al</i>. Intravitreal bevacizumab syringes. Working protocol. <i>European Journal of Clinical Pharmacy: Atención Farmacéutica</i>, 2013;<b>15</b>(N°5):351–357. Monzon Moreno A, <i>et al</i>. Ranibizumab y bevacizumab en el tratamiento del oedema macular diabético. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. 2014. <h3>Conflict of Interest</h3> No conflict of interest